1. Home
  2. VITL vs NVAX Comparison

VITL vs NVAX Comparison

Compare VITL & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vital Farms Inc.

VITL

Vital Farms Inc.

HOLD

Current Price

$20.14

Market Cap

944.3M

ML Signal

HOLD

NVAX

Novavax Inc.

HOLD

Current Price

$10.01

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VITL
NVAX
Founded
2007
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
944.3M
1.5B
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
VITL
NVAX
Price
$20.14
$10.01
Analyst Decision
Strong Buy
Hold
Analyst Count
9
9
Target Price
$42.56
$11.33
AVG Volume (30 Days)
2.1M
4.2M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
22.03
309.76
EPS
1.44
2.58
Revenue
$759,444,000.00
$1,123,479,000.00
Revenue This Year
$26.07
N/A
Revenue Next Year
$20.95
N/A
P/E Ratio
$13.90
$3.85
Revenue Growth
25.26
64.69
52 Week Low
$19.75
$5.01
52 Week High
$53.13
$11.85

Technical Indicators

Market Signals
Indicator
VITL
NVAX
Relative Strength Index (RSI) 23.04 57.06
Support Level N/A $6.34
Resistance Level $29.73 $10.42
Average True Range (ATR) 1.34 0.73
MACD -0.63 0.05
Stochastic Oscillator 2.93 46.53

Price Performance

Historical Comparison
VITL
NVAX

About VITL Vital Farms Inc.

Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Share on Social Networks: